AlphaMaven

Company Logo'

Hedge Fund

QCAM FX BIAS

QCAM Currency Asset Management
Request More Information

Investment Overview

Strategy Description

FX BIAS offers alternative investment investors a systematic methodology to gain exposure in liquid currencies. The rulebased strategy uses business sentiment surveys for 8 countries/currencies (USD, EUR, JPY, GBP, CHF, CAD, AUD and SEK) to build a diversified currency portfolio. Currency exposures are weighted towards more liquid currency pairs which are less driven by noise and/or large order flows. The returns are over time uncorrelated to traditional asset classes and common risk factors in FX markets.
Principals

Sabrina von Dach
Sabrina von Dach - Business Management, QCAM Currency Asset Management
Investment Highlights

Investment Category

Hedge Fund

Investment Strategy

Systematic, Currency Trading, Market Neutral

Investment Structure

Managed Account, SMA, AMC

Objective

Our Performance Goal
Uncorrelated Returns

Investment Opportunity

What We Believe
FX BIAS offers alternative investment investors a systematic methodology to gain exposure in liquid currencies.

Return Driver - Alpha

Our Edge
Uncorrelated Strategies
Implementation of Strategy
Tactical Approach

Market Sector Exposure

Currencies

Instruments Traded

Currencies

Geographical Exposure

Global

Average Timeframe

1-18 Months

Average Leverage Utilized (%)

145%

Risk Management

Diversification, Position Limits, Liquid Securities
Investment Structure

Legal Structure

Managed Accounts

Domicile

Switzerland

Fund Minimum Investment

$200K

Managed Account Minimum

$10MM

Strategy AUM

$4MM

Firm AUM

$5B

Management Fee (%)

1.3%

Incentive Fee (%)

15%
Service Providers

Administrator

UBS

Prime Broker

UBS

Custodian/Bank

NONE
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
You May Also Enjoy The Following Posts
Ridgedale MSP Partner Series - March 2024 Newsletter
1w ago HedgeFund Ridgedale MSP Partner Series
Exome Worldwide Healthcare Partners - March 2024 Investor Newsletter
2w ago HedgeFund Worldwide Healthcare Partners
Andrea Alms Video:  Money In Motion 101 - Deep Dive - Immunotherapy Cancer Market
2w ago PrivateEquity BrookDell Partners
Andrea Alms Video:  Money In Motion 98 - Radiation Therapy Market
1mo ago PrivateEquity BrookDell Partners
Andrea Alms Video:  Money In Motion 97 - The Chemotherapy Market
1mo ago PrivateEquity BrookDell Partners
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.